Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00200499 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients
A Phase 3 study, sponsored by Mylan Bertek Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 845
- Enrollment target
NCT00200499: Completed Phase 3 study, sponsored by Mylan Bertek Pharmaceuticals.
NCT00200499 is a Phase 3 study that has completed, run by Mylan Bertek Pharmaceuticals. The registered enrollment target is 845 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00200499, a Phase 3 study, has completed, sponsored by Mylan Bertek Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 845 participants
- Enrollment target
Study Summary
The study was conducted to determine the long-term safety and efficacy of nebivolol in patients with mild to moderate hypertension. This was an extension of the Phase III dose ranging studies NEB 202, 302 and 305. Nebivolol was studied as monotherapy and in conjunction with add-on antihypertensive therapy.
Interventions
- DRUG Nebivolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 845 participants |
| Start Date | 2002-03 |
| Est. Completion | 2003-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00200499
The ClinicalTrials.gov registry entry for NCT00200499 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 845 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Bertek Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nebivolol is the first listed.
NCT00200499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00200499 about?
NCT00200499 is a clinical study titled "A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients". The study was conducted to determine the long-term safety and efficacy of nebivolol in patients with mild to moderate hypertension. This was an extension of the Phase III dose ranging studies NEB 202, 302 and 305. Nebivolol was studied as monotherapy and in conjunction with add-on antihypertensive t...
What is the current status of trial NCT00200499?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 845 participants. The study started on 2002-03. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00200499?
The interventions under investigation include: Nebivolol (DRUG).
Who is sponsoring clinical trial NCT00200499?
This trial is sponsored by Mylan Bertek Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.